Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial

References

• Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039–21.
   PubMed Web of Science ®Google Scholar
• Gottschalk TA, Tsantikos E, Hibbs ML. Pathogenic inflammation and its therapeutic targeting in systemic lupus erythematosus. Front Immunol. 2015;6:550.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–31.
   PubMed Web of Science ®Google Scholar
• Zhang J, Roschke V, Baker KP, Wang Z, Alarcón GS, Fessler BJ, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001;166(1):6–10.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kubo S, Iwata S, Yoshikawa M, Nakayamada S. B cell phenotypes, signaling and their roles in secretion of antibodies in systemic lupus erythematosus. Clin Immunol. 2017;186:21–5
   PubMed Web of Science ®Google Scholar
• Kuhn A, Bonsmann G, Anders HJ, Herzer P, Tenbrock K, Schneider M. The diagnosis and treatment of systemic lupus erythematosus. Dtsch Ärztebl Int. 2015;112(25):423.
   PubMed Web of Science ®Google Scholar
• Furie R, Petri MA, Strand V, Gladman DD, Zhong ZJ, Freimuth WW. Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. Lupus Sci Med. 2014;1(1):e000031.
   PubMedGoogle Scholar
• Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis. 2014;73(5):838–44.
   PubMed Web of Science ®Google Scholar
• Bertsias G, Ioannidis J, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus (SLE) report of a task force of the European standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis. 2007; 67(2):195–205.
   PubMed Web of Science ®Google Scholar
• Bruce IN, O'Keeffe AG, Farewell V, Hanly JG, Manzi S, Su L, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015;74(9):1706–13.
   PubMed Web of Science ®Google Scholar
• Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther. 2012;14 (l4):S4.
   PubMedGoogle Scholar
• Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308–18.
   PubMed Web of Science ®Google Scholar
• Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res. 2012;64(2):159–68.
   PubMed Web of Science ®Google Scholar
• Ohta A, Nagai M, Nishina M, Tomimitsu H, Kohsaka H. Age at onset and gender distribution of systemic lupus erythematosus, polymyositis/dermatomyositis, and systemic sclerosis in Japan. Mod Rheumatol. 2013;23(4):759–64.
   PubMed Web of Science ®Google Scholar
• Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48(11):3253–65.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Summary of product characteristics. 2011. Available from:http://www.ema.europa.eu/ema/ [last accessed 06 June 2017].
   Google Scholar
• Food and Drug Administration (FDA). FDA approves Benlysta to treat lupus. 2011. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm246489.htm [last accessed 06 June 2017].
   Google Scholar
• GSK. GSK receives approval for Benlysta in Japan for the treatment of systemic lupus erythematosus. 2017. Available from: https://us.gsk.com/en-us/media/press-releases/2017/gsk-receives-approval-for-benlysta-in-japan-for-the-treatment-of-systemic-lupus-erythematosus/ [last accessed 27 September 2017].
   Google Scholar
• Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–30.
   PubMed Web of Science ®Google Scholar
• Zhang F, Bae SC, Bass D, Chu M, Egginton S, Gordon D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018;77(3):355–363.
   PubMed Web of Science ®Google Scholar
• World Medical Association. WMA Declaration of Helsinki - ethical principles for medical research involving human subjects. 2008. Available from: http://www.wma.net/en/30publications/10policies/b3/index.html [last accessed 06 June 2017].
   Google Scholar
• Struemper H, Chen C, Cai W. Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus. J Clin Pharmacol. 2013;53(7):711–20.
   PubMed Web of Science ®Google Scholar
• Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2017;69(5):1016–27.
   PubMed Web of Science ®Google Scholar
• Gatto M, Saccon F, Zen M, Bettio S, Iaccarino L, Punzi L, et al. Success and failure of biological treatment in systemic lupus erythematosus: a critical analysis. J Autoimmun. 2016;74:94–105.
   PubMed Web of Science ®Google Scholar
• Yamada M, Akita M, Nakagawa T, Takahashi N, Endo A, Yoshida P. Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to- moderate systemic lupus erythematosus. J Drug Assess. 2013;2(1):40–8.
   PubMedGoogle Scholar
• Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64(7):2328–37.
   PubMed Web of Science ®Google Scholar
• Halpern WG, Lappin P, Zanardi T, Cai W, Corcoran M, Zhong J, et al. Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects. Toxicol Sci. 2006;91(2):586–99.
   PubMed Web of Science ®Google Scholar
• Badr G, Borhis G, Lefevre EA, Chaoul N, Deshayes F, Dessirier V, et al. BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells. Blood. 2008;111(5):2744–54.
   PubMed Web of Science ®Google Scholar